Advertisement
Screener

ARMATA PHARMACEUTICALS, INC. (ARMP) Net Cash Provided by (Used in) Investing Activities, Continuing Operations

2.5 / 5 stars · 32/64 Roast Me

ARMATA PHARMACEUTICALS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations

ARMATA PHARMACEUTICALS, INC. (ARMP) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$40.00 thousand for the 9-month period ending 2017-09-30, per its 10-Q filed 2017-11-14.

Discontinued › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2017-11-14

  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$33.00K.
  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$2.00K.
  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$5.00K.
  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2016-12-31 was -$13.00K.
  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$279.00K.
  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$210.00K.
  • ARMATA PHARMACEUTICALS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$1.20M.
Period endNet Cash Provided by (Used in) Investing Activities, Continuing Operations 3 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 6 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 9 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filedNet Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month
2017-09-30-$33.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14
-$35.00K
derived: sum of 2 quarters · filed 2017-11-14
-$40.00K
10-Q · filed 2017-11-14
-$53.00K
derived: sum of 4 quarters · filed 2017-11-14
2017-06-30-$2.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14
-$7.00K
10-Q · filed 2017-08-14
-$20.00K
derived: sum of 3 quarters · filed 2017-08-14
-$49.00K
derived: sum of 4 quarters · filed 2017-11-14
2017-03-31-$5.00K
10-Q · filed 2017-05-15
-$18.00K
derived: sum of 2 quarters · filed 2017-05-15
-$47.00K
derived: sum of 3 quarters · filed 2017-11-14
-$172.00K
derived: sum of 4 quarters · filed 2017-11-14
2016-12-31-$13.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-27
-$42.00K
derived: sum of 2 quarters · filed 2017-11-14
-$167.00K
derived: sum of 3 quarters · filed 2017-11-14
-$279.00K
10-K · filed 2017-03-27
2016-09-30-$29.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14
-$154.00K
derived: sum of 2 quarters · filed 2017-11-14
-$266.00K
10-Q · filed 2017-11-14
-$316.00K
derived: sum of 4 quarters · filed 2017-11-14
2016-06-30-$125.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14
-$237.00K
10-Q · filed 2017-08-14
-$287.00K
derived: sum of 3 quarters · filed 2017-08-14
-$403.00K
derived: sum of 4 quarters · filed 2017-08-14
2016-03-31-$112.00K
10-Q · filed 2017-05-15
-$162.00K
derived: sum of 2 quarters · filed 2017-05-15
-$278.00K
derived: sum of 3 quarters · filed 2017-05-15
-$287.00K
derived: sum of 4 quarters · filed 2017-05-15
2015-12-31-$50.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-27
-$166.00K
derived: sum of 2 quarters · filed 2017-03-27
-$175.00K
derived: sum of 3 quarters · filed 2017-03-27
-$210.00K
10-K · filed 2017-03-27
2015-09-30-$116.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10
-$125.00K
derived: sum of 2 quarters · filed 2016-11-10
-$160.00K
10-Q · filed 2016-11-10
-$165.00K
derived: sum of 4 quarters · filed 2016-11-10
2015-06-30-$9.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15
-$44.00K
10-Q · filed 2016-08-15
-$49.00K
derived: sum of 3 quarters · filed 2016-08-15
-$186.00K
derived: sum of 4 quarters · filed 2016-08-15
2015-03-31-$35.00K
10-Q · filed 2016-05-12
-$40.00K
derived: sum of 2 quarters · filed 2016-05-12
-$177.00K
derived: sum of 3 quarters · filed 2016-05-12
-$1.01M
derived: sum of 4 quarters · filed 2016-05-12
2014-12-31-$5.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30
-$142.00K
derived: sum of 2 quarters · filed 2016-03-30
-$973.00K
derived: sum of 3 quarters · filed 2016-03-30
-$1.20M
10-K · filed 2016-03-30
2014-09-30-$137.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-16
-$968.00K
derived: sum of 2 quarters · filed 2015-11-16
-$1.20M
10-Q · filed 2015-11-16
-$1.09M
10-Q · filed 2014-11-14
-$1.20M
derived: sum of 4 quarters · filed 2015-11-16
2014-06-30-$831.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13
-$1.06M
10-Q · filed 2015-08-13
-$1.06M
derived: sum of 3 quarters · filed 2015-08-13
-$1.10M
derived: sum of 4 quarters · filed 2015-08-13
2014-03-31-$229.00K
10-Q · filed 2015-05-15
-$234.00K
derived: sum of 2 quarters · filed 2015-05-15
-$266.00K
derived: sum of 3 quarters · filed 2015-05-15
-$331.00K
derived: sum of 4 quarters · filed 2015-05-15
2013-12-31-$5.00K
derived: 10-Q/A 12 month − 10-Q/A 9 month · filed 2015-04-15
-$37.00K
derived: sum of 2 quarters · filed 2015-04-15
-$102.00K
derived: sum of 3 quarters · filed 2015-04-15
-$102.00K
10-Q/A · filed 2015-04-15
2013-09-30-$32.00K
derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2015-04-15
-$97.00K
derived: sum of 2 quarters · filed 2015-04-15
-$97.00K
10-Q/A · filed 2015-04-15
2013-06-30-$65.00K
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2015-04-15
-$65.00K
10-Q/A · filed 2015-04-15
2013-03-31$0.00
10-Q/A · filed 2015-04-15

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neumora Therapeutics, Inc. (NMRA)United States$0.132B-1.48
Caribou Biosciences, Inc. (CRBU)United States$0.134B-1.79
enGene Therapeutics Inc. (ENGN)$0.129B-0.92
Tenaya Therapeutics, Inc. (TNYA)United States$0.140B-1.60
LENZ Therapeutics, Inc. (LENZ)United States$0.117B-1.41
Humacyte, Inc. (HUMA)United States$0.155B-2.26
Black Diamond Therapeutics, Inc. (BDTX)United States$0.109B-2.48
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22